Genetic profiling of CLL: a ‘TP53 addict’ perspective

Chronic lymphocytic leukaemia (CLL) is a B-cell malignancy with a highly variable clinical course. Whereas some patients require treatment relatively soon after diagnosis, others may stay free of symptoms for many years with a standard ‘watch and wait’ surveillance approach. Genomic analysis of asymptomatic patients and patients with progressive or relapsed refractory disease makes CLL an excellent model to study the course of genetic modifications in relation to the pathobiology of this disease.

Domaines

Hématologie

Fichier principal

cddis2015415.pdf (255.28 Ko)

Origine	Publication financée par une institution
Licence	Autorisation HAL

Connectez-vous pour contacter le contributeur

https://hal.sorbonne-universite.fr/hal-01332729

Soumis le : mercredi 16 octobre 2019-14:33:30

Dernière modification le : lundi 23 septembre 2024-13:28:02

Archivage à long terme le : vendredi 17 janvier 2020-15:09:39

Dates et versions

hal-01332729 , version 1 (16-10-2019)

Licence

Autorisation HAL

Identifiants

HAL Id : hal-01332729 , version 1
DOI : 10.1038/cddis.2015.415
PUBMEDCENTRAL : PMC4816188

Citer

L Lodé, F Cymbalista, Thierry Soussi. Genetic profiling of CLL: a ‘TP53 addict’ perspective. Cell Death and Disease, 2016, 7 (1), pp.e2042. ⟨10.1038/cddis.2015.415⟩. ⟨hal-01332729⟩